BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch- New electric car registrations rise sharply in Germany in March
- Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Discovery of massive spider's web in Greece reveals unexpected behavior
- The 10 Most Noteworthy Games in History
